Trial Profile

Research on the blood concentration of ponatinib and treatment outcome in patients with chronic phase chronic myelogenous leukemia (CP-CML)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ponatinib (Primary)
Indications Chronic myeloid leukaemia
Focus Pharmacokinetics
Sponsors Otsuka Pharmaceutical

Most Recent Events

01 Feb 2022 According to UMIN, the date for trial data considered completed is 31 Dec 2022, and date of conclusion of data analysis is 31 Mar 2023.
01 Feb 2022 Planned End Date changed from 30 Jun 2023 to 30 Sep 2022.
01 Feb 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com